Skip to content

BrightPoint Reflectometer Device Study

Human Clinical Trial to Evaluate the BRIGHTPOINT Reflectometer Device as Secondary Confirmation to Loss of Resistance in Lumbar Epidural Placement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05616299
Enrollment
3
Registered
2022-11-15
Start date
2023-04-28
Completion date
2023-06-23
Last updated
2023-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidural Placement

Keywords

Labor, Epidural

Brief summary

Participants are being asked to participate in this study because they are having an epidural placed for labor. This human clinical trial has been designed to evaluate the use of the BrightPoint Reflectometer Device (AKA BrightPoint device) as secondary confirmation of Loss of Residence (LOR) for lumbar epidural placement by an experienced clinician. For this study, participants will be randomized to receive an epidural by an experienced clinician either with or without the use of the BrightPoint device. Epidurals performed as a part of this study will be done in a manner similar to how epidurals are currently performed in the hospital. The epidural space will be entered using usual loss of resistance technique for all patients. If the BrightPoint device is used, it will be as secondary verification of entry into the epidural space.

Interventions

DEVICEBrightPoint

Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.

Sponsors

Lumoptik, Inc.
CollaboratorUNKNOWN
University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

* Any patient undergoing an epidural procedure

Exclusion criteria

* Previous lumbar spine surgery * Any known spinal abnormality that would interferre with successfully advancing a needle into the epidural space * Any subject that requires an epidural needle longer than 4.0 inches * Any procedure requiring use of CSE needles * Any contraindication to neuraxial anesthesia * No subjects in advanced active labor, e.g., 6-8 cm dilated * Tattoo at the site of epidural insertion

Design outcomes

Primary

MeasureTime frameDescription
Number of times the BrightPoint device was able to measure Loss of Residence (LOR) accurately.Up to 90 minutesThis is measured as a Yes or No response.

Secondary

MeasureTime frame
Number of times the device indicated the needle tip was entering the LF as measured by clinician logUp to 20 minutes
Number of times epidural accessed while using BrightPoint device as measured by clinical logUp to 90 minutes
Number of times epidural catheter was used during the procedure as measured by clinical logUp to 20 minutes
Number of adverse events as measured by clinician logUp to 90 minutes
Number of times the BrightPoint device provided real-time secondary confirmation of Loss of Residence (LOR) as measured by clinician logUp to 90 minutes
Number of times the BrightPoint device provided beneficial qualitative/quantitative clinical information to help complete the epidural as measured by clinician log.Up to 90 minutes
Number of times clinician experienced the haptic feel of entering the ligamentum flavum (LF) as measured by clinician logUp to 90 minutes
Number of times there were issues achieving pain management as measured by clinician logUp to 4 hours
Number of times clinician experienced the haptic sensation of the needle contacting any tissue that was not expected as measured by clinician logUp to 90 minutes
Number of times there were issues with catheterization as measured by clinician logUp to 90 minutes
Number of times the device showed a significant change of color from the light in LF to the dark in ES as measured by clinician logUp to 90 minutes
Number of times the device showed a significant change of reflectance from high in LF to low in ES as measured by clinician logUp to 90 minutes
Number of times the LOR and BrightPoint device agreed as measured by clinician logUp to 90 minutes
Number of times coring was observed during procedure as measured by clinician logUp to 90 minutes
Number of times the BrightPoint interfered with the ability to perform the epidural placement in the usual manner with LOR and haptic feedback as measured by clinician logUp to 90 minutes
Number of times clinician experienced LOR after entering the epidural space as measured by clinician logUp to 90 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026